ALLO250117P2000
- 0.20
- +0.09+81.82%
Allogene Therapeutics Newsroom
Piper Sandler Maintains Allogene Therapeutics(ALLO.US) With Buy Rating, Maintains Target Price $9
JMP Securities Maintains Allogene Therapeutics(ALLO.US) With Hold Rating
Piper Sandler Maintains Allogene Therapeutics(ALLO.US) With Buy Rating, Cuts Target Price to $9
Allogene Therapeutics Analyst Ratings
Piper Sandler Maintains Overweight on Allogene Therapeutics, Lowers Price Target to $9
William Blair Maintains Allogene Therapeutics(ALLO.US) With Buy Rating
TD Cowen Maintains Allogene Therapeutics(ALLO.US) With Buy Rating
Stifel Maintains Allogene Therapeutics(ALLO.US) With Hold Rating, Cuts Target Price to $4.5
JMP Securities Maintains Allogene Therapeutics(ALLO.US) With Hold Rating
Allogene Therapeutics Price Target Maintained With a $9.00/Share by HC Wainwright & Co.
Analysts Offer Insights on Healthcare Companies: Cartesian Therapeutics (RNAC), Allogene Therapeutics (ALLO) and Moderna (MRNA)
TD Cowen Maintains Allogene Therapeutics(ALLO.US) With Buy Rating
RBC Capital Maintains Allogene Therapeutics(ALLO.US) With Buy Rating, Maintains Target Price $10
William Blair Maintains Allogene Therapeutics(ALLO.US) With Buy Rating
TD Cowen Maintains Allogene Therapeutics(ALLO.US) With Buy Rating
Allogene Therapeutics Analyst Ratings
H.C. Wainwright Maintains Allogene Therapeutics(ALLO.US) With Buy Rating, Maintains Target Price $9
Analysts Offer Insights on Healthcare Companies: Indivior (GB:INDV), Vor Biopharma (VOR) and Allogene Therapeutics (ALLO)
Allogene Therapeutics Price Target Maintained With a $9.00/Share by HC Wainwright & Co.
Allogene Therapeutics Analyst Ratings